{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:50:50Z","timestamp":1760986250930,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Balovaptan is a brain-penetrating vasopressin receptor 1a antagonist previously investigated for the core symptoms of autism spectrum disorder (ASD). A population pharmacokinetic (PK) model of balovaptan was developed, initially to assist clinical dosing for adult and pediatric ASD studies and subsequently for new clinical indications including malignant cerebral edema (MCE) and post-traumatic stress disorder. The final model incorporates one-compartment disposition and describes time- and dose-dependent non-linear PK through empirical drug binding and a gut extraction component with turnover. An age effect on clearance observed in children was modeled by an asymptotic function that predicts adult-equivalent exposures at 40% of the adult dose for children aged 2\u20134\u00a0years, 70% for 5\u20139\u00a0years, and at the full adult dose for\u2009\u2265\u200910\u00a0years. The model was adapted for intravenous (IV) balovaptan dosing and combined with in vitro and ex vivo pharmacodynamic data to simulate brain receptor occupancy as a guide for dosing in a phase II trial of MCE prophylaxis after acute ischemic stroke. A sequence of three stepped-dose daily infusions of 50, 25 and 15\u00a0mg over 30 or 60\u00a0min was predicted to achieve a target occupancy of\u2009\u2265\u200980% in\u2009\u2265\u200995% of patients over a 3-day period. This model predicts both oral and IV balovaptan exposure across a wide age range and will be a valuable tool to analyze and predict its PK in new indications and target populations, including pediatric patients.<\/jats:p>","DOI":"10.1007\/s10928-023-09898-0","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T13:02:26Z","timestamp":1706965346000},"page":"227-242","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5692-3448","authenticated-orcid":false,"given":"Franziska","family":"Schaedeli Stark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clarisse","family":"Chavanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4918-7828","authenticated-orcid":false,"given":"Michael","family":"Derks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5920-8146","authenticated-orcid":false,"given":"Koen","family":"Jolling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5118-4247","authenticated-orcid":false,"given":"Hendrik Maxime","family":"Lagraauw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Lindbom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8665-2138","authenticated-orcid":false,"given":"Klaas","family":"Prins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4928-6284","authenticated-orcid":false,"given":"Hanna E.","family":"Silber Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"issue":"10","key":"9898_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s1043-2760(00)00304-0","volume":"11","author":"M Birnbaumer","year":"2000","unstructured":"Birnbaumer M (2000) Vasopressin receptors. Trends Endocrinol Metab 11(10):406\u2013410. https:\/\/doi.org\/10.1016\/s1043-2760(00)00304-0","journal-title":"Trends Endocrinol Metab"},{"issue":"4","key":"9898_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/1097-4547(20001115)62:4<480::AID-JNR2>3.0.CO;2-K","volume":"62","author":"L Hertz","year":"2000","unstructured":"Hertz L, Chen Y, Spatz M (2000) Involvement of non-neuronal brain cells in AVP-mediated regulation of water space at the cellular, organ, and whole-body level. J Neurosci Res 62(4):480\u2013490. https:\/\/doi.org\/10.1002\/1097-4547(20001115)62:4%3c480::AID-JNR2%3e3.0.CO;2-K","journal-title":"J Neurosci Res"},{"issue":"9","key":"9898_CR3","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1523\/JNEUROSCI.21-09-03045.2001","volume":"21","author":"H Niermann","year":"2001","unstructured":"Niermann H, Amiry-Moghaddam M, Holthoff K, Witte OW, Ottersen OP (2001) A novel role of vasopressin in the brain: modulation of activity-dependent water flux in the neocortex. J Neurosci 21(9):3045\u20133051","journal-title":"J Neurosci"},{"issue":"1","key":"9898_CR4","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0006-8993(78)90766-7","volume":"143","author":"ME Raichle","year":"1978","unstructured":"Raichle ME, Grubb RL Jr (1978) Regulation of brain water permeability by centrally-released vasopressin. Brain Res 143(1):191\u2013194. https:\/\/doi.org\/10.1016\/0006-8993(78)90766-7","journal-title":"Brain Res"},{"issue":"20","key":"9898_CR5","doi-asserted-by":"publisher","first-page":"7807","DOI":"10.1073\/pnas.0600875103","volume":"103","author":"TA Koshimizu","year":"2006","unstructured":"Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G (2006) V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci USA 103(20):7807\u20137812. https:\/\/doi.org\/10.1073\/pnas.0600875103","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3\u20134","key":"9898_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.yfrne.2004.09.001","volume":"25","author":"M Engelmann","year":"2004","unstructured":"Engelmann M, Landgraf R, Wotjak CT (2004) The hypothalamic-neurohypophysial system regulates the hypothalamic-pituitary-adrenal axis under stress: an old concept revisited. Front Neuroendocrinol 25(3\u20134):132\u2013149. https:\/\/doi.org\/10.1016\/j.yfrne.2004.09.001","journal-title":"Front Neuroendocrinol"},{"issue":"1476","key":"9898_CR7","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1098\/rstb.2006.1939","volume":"361","author":"EA Hammock","year":"2006","unstructured":"Hammock EA, Young LJ (2006) Oxytocin, vasopressin and pair bonding: implications for autism. Philos Trans R Soc Lond B Biol Sci 361(1476):2187\u20132198. https:\/\/doi.org\/10.1098\/rstb.2006.1939","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"6","key":"9898_CR8","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.neuron.2010.03.005","volume":"65","author":"TR Insel","year":"2010","unstructured":"Insel TR (2010) The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior. Neuron 65(6):768\u2013779. https:\/\/doi.org\/10.1016\/j.neuron.2010.03.005","journal-title":"Neuron"},{"issue":"5","key":"9898_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/sj.mp.4001125","volume":"7","author":"SJ Kim","year":"2002","unstructured":"Kim SJ, Young LJ, Gonen D, Veenstra-VanderWeele J, Courchesne R, Courchesne E, Lord C, Leventhal BL, Cook EH Jr, Insel TR (2002) Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry 7(5):503\u2013507. https:\/\/doi.org\/10.1038\/sj.mp.4001125","journal-title":"Mol Psychiatry"},{"key":"9898_CR10","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7356","author":"KJ Parker","year":"2019","unstructured":"Parker KJ, Oztan O, Libove RA, Mohsin N, Karhson DS, Sumiyoshi RD, Summers JE, Hinman KE, Motonaga KS, Phillips JM, Carson DS, Fung LK, Garner JP, Hardan AY (2019) A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aau7356","journal-title":"Sci Transl Med"},{"issue":"1","key":"9898_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2040-2392-2-3","volume":"2","author":"KE Tansey","year":"2011","unstructured":"Tansey KE, Hill MJ, Cochrane LE, Gill M, Anney RJ, Gallagher L (2011) Functionality of promoter microsatellites of arginine vasopressin receptor 1A (AVPR1A): implications for autism. Mol Autism 2(1):3. https:\/\/doi.org\/10.1186\/2040-2392-2-3","journal-title":"Mol Autism"},{"issue":"10","key":"9898_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/sj.mp.4001503","volume":"9","author":"TH Wassink","year":"2004","unstructured":"Wassink TH, Piven J, Vieland VJ, Pietila J, Goedken RJ, Folstein SE, Sheffield VC (2004) Examination of AVPR1a as an autism susceptibility gene. Mol Psychiatry 9(10):968\u2013972. https:\/\/doi.org\/10.1038\/sj.mp.4001503","journal-title":"Mol Psychiatry"},{"issue":"3","key":"9898_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.neulet.2010.05.050","volume":"479","author":"SY Yang","year":"2010","unstructured":"Yang SY, Cho SC, Yoo HJ, Cho IH, Park M, Kim BN, Kim JW, Shin MS, Park TW, Son JW, Chung US, Kim HW, Yang YH, Kang JO, Kim SA (2010) Association study between single nucleotide polymorphisms in promoter region of AVPR1A and Korean autism spectrum disorders. Neurosci Lett 479(3):197\u2013200. https:\/\/doi.org\/10.1016\/j.neulet.2010.05.050","journal-title":"Neurosci Lett"},{"key":"9898_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13229-017-0161-9","volume":"8","author":"SY Yang","year":"2017","unstructured":"Yang SY, Kim SA, Hur GM, Park M, Park JE, Yoo HJ (2017) Replicative genetic association study between functional polymorphisms in AVPR1A and social behavior scales of autism spectrum disorder in the Korean population. Mol Autism 8:44. https:\/\/doi.org\/10.1186\/s13229-017-0161-9","journal-title":"Mol Autism"},{"issue":"5","key":"9898_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/sj.mp.4001812","volume":"11","author":"N Yirmiya","year":"2006","unstructured":"Yirmiya N, Rosenberg C, Levi S, Salomon S, Shulman C, Nemanov L, Dina C, Ebstein RP (2006) Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry 11(5):488\u2013494. https:\/\/doi.org\/10.1038\/sj.mp.4001812","journal-title":"Mol Psychiatry"},{"issue":"6","key":"9898_CR16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1080\/10253890.2020.1826430","volume":"23","author":"E Sipos","year":"2020","unstructured":"Sipos E, Torok B, Barna I, Engelmann M, Zelena D (2020) Vasopressin and post-traumatic stress disorder. Stress 23(6):732\u2013745. https:\/\/doi.org\/10.1080\/10253890.2020.1826430","journal-title":"Stress"},{"key":"9898_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neures.2017.10.007","volume":"129","author":"Y Yamaguchi","year":"2018","unstructured":"Yamaguchi Y (2018) Arginine vasopressin signaling in the suprachiasmatic nucleus on the resilience of circadian clock to jet lag. Neurosci Res 129:57\u201361. https:\/\/doi.org\/10.1016\/j.neures.2017.10.007","journal-title":"Neurosci Res"},{"issue":"1","key":"9898_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40345-021-00233-5","volume":"9","author":"P Vidafar","year":"2021","unstructured":"Vidafar P, Yocum AK, Han P, McInnis MG, Burgess HJ (2021) Late chronotype predicts more depressive symptoms in bipolar disorder over a 5 year follow-up period. Int J Bipolar Disord 9(1):28. https:\/\/doi.org\/10.1186\/s40345-021-00233-5","journal-title":"Int J Bipolar Disord"},{"issue":"9","key":"9898_CR19","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/jnr.23407","volume":"92","author":"PA Ameli","year":"2014","unstructured":"Ameli PA, Ameli NJ, Gubernick DM, Ansari S, Mohan S, Satriotomo I, Buckley AK, Maxwell CW Jr, Nayak VH, Shushrutha Hedna V (2014) Role of vasopressin and its antagonism in stroke related edema. J Neurosci Res 92(9):1091\u20131099. https:\/\/doi.org\/10.1002\/jnr.23407","journal-title":"J Neurosci Res"},{"issue":"4","key":"9898_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/jcbfm.1992.93","volume":"12","author":"LD Dickinson","year":"1992","unstructured":"Dickinson LD, Betz AL (1992) Attenuated development of ischemic brain edema in vasopressin-deficient rats. J Cereb Blood Flow Metab 12(4):681\u2013690. https:\/\/doi.org\/10.1038\/jcbfm.1992.93","journal-title":"J Cereb Blood Flow Metab"},{"key":"9898_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/bs.vh.2019.08.015","volume":"113","author":"E Zeynalov","year":"2020","unstructured":"Zeynalov E, Jones SM, Elliott JP (2020) Vasopressin and vasopressin receptors in brain edema. Vitam Horm 113:291\u2013312. https:\/\/doi.org\/10.1016\/bs.vh.2019.08.015","journal-title":"Vitam Horm"},{"issue":"4","key":"9898_CR22","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1021\/acs.jmedchem.9b01478","volume":"63","author":"P Schnider","year":"2020","unstructured":"Schnider P, Bissantz C, Bruns A, Dolente C, Goetschi E, Jakob-Roetne R, Kunnecke B, Mueggler T, Muster W, Parrott N, Pinard E, Ratni H, Risterucci C, Rogers-Evans M, von Kienlin M, Grundschober C (2020) Discovery of balovaptan, a vasopressin 1a receptor antagonist for the treatment of autism spectrum disorder. J Med Chem 63(4):1511\u20131525. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01478","journal-title":"J Med Chem"},{"key":"9898_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7838","author":"F Bolognani","year":"2019","unstructured":"Bolognani F, Del Valle RM, Squassante L, Wandel C, Derks M, Murtagh L, Sevigny J, Khwaja O, Umbricht D, Fontoura P (2019) A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aat7838","journal-title":"Sci Transl Med"},{"issue":"8","key":"9898_CR24","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamapsychiatry.2022.1717","volume":"79","author":"E Hollander","year":"2022","unstructured":"Hollander E, Jacob S, Jou R, McNamara N, Sikich L, Tobe R, Smith J, Sanders K, Squassante L, Murtagh L, Gleissl T, Wandel C, Veenstra-VanderWeele J (2022) Balovaptan vs placebo for social communication in childhood autism spectrum disorder: a randomized clinical trial. JAMA Psychiat 79(8):760\u2013769. https:\/\/doi.org\/10.1001\/jamapsychiatry.2022.1717","journal-title":"JAMA Psychiat"},{"issue":"3","key":"9898_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S2215-0366(21)00429-6","volume":"9","author":"S Jacob","year":"2022","unstructured":"Jacob S, Veenstra-VanderWeele J, Murphy D, McCracken J, Smith J, Sanders K, Meyenberg C, Wiese T, Deol-Bhullar G, Wandel C, Ashford E, Anagnostou E (2022) Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial. Lancet Psychiatry 9(3):199\u2013210. https:\/\/doi.org\/10.1016\/S2215-0366(21)00429-6","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"9898_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/13543784.2021.1948009","volume":"30","author":"M Derks","year":"2021","unstructured":"Derks M, Lennon-Chrimes S, Guenther A, Squassante L, Wandel C, Szczesny P, Paehler A, Kletzl H (2021) Bioavailability and pharmacokinetic profile of balovaptan, a selective, brain-penetrant vasopressin 1a receptor antagonist, in healthy volunteers. Expert Opin Investig Drugs 30(8):893\u2013901. https:\/\/doi.org\/10.1080\/13543784.2021.1948009","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"9898_CR27","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1007\/s12325-020-01491-y","volume":"37","author":"MGM Derks","year":"2020","unstructured":"Derks MGM, Wandel C, Young A, Bolt SK, Meyenberg C (2020) Open-Label assessment of the effects of itraconazole and rifampicin on balovaptan pharmacokinetics in healthy volunteers. Adv Ther 37(11):4720\u20134729. https:\/\/doi.org\/10.1007\/s12325-020-01491-y","journal-title":"Adv Ther"},{"issue":"1","key":"9898_CR28","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.euroneuro.2020.09.110","volume":"40","author":"F Schaedeli Stark","year":"2020","unstructured":"Schaedeli Stark F, Chavanne C, Lennon-Chrimes S, Diack C, Derks M, Smith J (2020) P.133 Paediatric dosing of balovaptan for the treatment of the core symptoms of autism spectrum disorder: data from a phase 2 study (aV1ation; NCT02901431). Eur Neuropsychopharmacol 40(1):82\u201383. https:\/\/doi.org\/10.1016\/j.euroneuro.2020.09.110","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"9898_CR29","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/cpt.2548","volume":"111","author":"A Varrone","year":"2022","unstructured":"Varrone A, Bundgaard C, Bang-Andersen B (2022) PET as a translational tool in drug development for neuroscience compounds. Clin Pharm Therap 111(4):774\u2013785. https:\/\/doi.org\/10.1002\/cpt.2548","journal-title":"Clin Pharm Therap"},{"issue":"5","key":"9898_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34(5):711\u2013726. https:\/\/doi.org\/10.1007\/s10928-007-9066-0","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9898_CR31","doi-asserted-by":"publisher","first-page":"F632","DOI":"10.1152\/ajprenal.1984.247.4.F632","volume":"247","author":"P Boer","year":"1984","unstructured":"Boer P (1984) Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol 247(4):F632\u2013F636. https:\/\/doi.org\/10.1152\/ajprenal.1984.247.4.F632","journal-title":"Am J Physiol"},{"issue":"5","key":"9898_CR32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/bja\/aer057","volume":"106","author":"AM Peters","year":"2011","unstructured":"Peters AM, Snelling HLR, Glass DM, Bird NJ (2011) Estimation of lean body mass in children. Br J Anaesth 106(5):719\u2013723. https:\/\/doi.org\/10.1093\/bja\/aer057","journal-title":"Br J Anaesth"},{"issue":"2","key":"9898_CR33","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13(2):143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"issue":"5","key":"9898_CR34","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1172\/JCI112179","volume":"76","author":"M Thibonnier","year":"1985","unstructured":"Thibonnier M, Roberts JM (1985) Characterization of human platelet vasopressin receptors. J Clin Invest 76(5):1857\u20131864","journal-title":"J Clin Invest"},{"issue":"4","key":"9898_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.1988.tb02886.x","volume":"29","author":"K Inaba","year":"1988","unstructured":"Inaba K, Umeda Y, Yamane Y, Urakami M, Inada M (1988) Characterization of human platelet vasopressin receptor and the relation between vasopressin-induced platelet aggregation and vasopressin binding to platelets. Clin Endocrinol 29(4):377\u2013386. https:\/\/doi.org\/10.1111\/j.1365-2265.1988.tb02886.x","journal-title":"Clin Endocrinol"},{"issue":"12","key":"9898_CR36","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/j.drudis.2018.06.010","volume":"23","author":"DA Smith","year":"2018","unstructured":"Smith DA, Van Waterschoot RA, Parrott NJ, Olivares-Morales A, Lav\u00e9 T, Rowland M (2018) Importance of target-mediated drug disposition for small molecules. Drug Discov Today 23(12):2023\u20132030","journal-title":"Drug Discov Today"},{"key":"9898_CR37","unstructured":"Derks M, Wandel C, Jordan P, Scoon S, Young A, Bolt S (2020) No clinically relevant effect of balovaptan on electrocardiography, heart rate or blood pressure in healthy volunteers (abstract 416.003). In: Proceedings and abstracts of the international society for autism research virtual meeting 2020 (June 3). pp 309\u2013310. https:\/\/insar.confex.com\/insar\/f\/noxeeosbroze. Accessed Nov 2022"},{"issue":"3","key":"9898_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","volume":"21","author":"BJ Anderson","year":"2011","unstructured":"Anderson BJ, Holford NH (2011) Tips and traps analyzing pediatric PK data. Paediatr Anaesth 21(3):222\u2013237. https:\/\/doi.org\/10.1111\/j.1460-9592.2011.03536.x","journal-title":"Paediatr Anaesth"},{"key":"9898_CR39","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40262-023-01241-7","volume":"62","author":"Y Cleary","year":"2023","unstructured":"Cleary Y, Kletzl H, Grimsey P, Heinig K, Ogungbenro K, Silber Baumann HE, Frey N, Aarons L, Galetin A, Gertz M (2023) Estimation of FMO3 ontogeny by mechanistic population pharmacokinetic modelling of risdiplam and its impact on drug\u2013drug interactions in children. Clin Pharmacokinet 62:891\u2013904. https:\/\/doi.org\/10.1007\/s40262-023-01241-7","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"9898_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jcph.585","volume":"56","author":"VV Upreti","year":"2016","unstructured":"Upreti VV, Wahlstrom JL (2016) Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol 56(3):266\u2013283. https:\/\/doi.org\/10.1002\/jcph.585","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"9898_CR41","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.pharmthera.2009.03.002","volume":"122","author":"S Grimwood","year":"2009","unstructured":"Grimwood S, Hartig PR (2009) Target site occupancy: emerging generalizations from clinical and preclinical studies. Pharmacol Ther 122(3):281\u2013301. https:\/\/doi.org\/10.1016\/j.pharmthera.2009.03.002","journal-title":"Pharmacol Ther"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-023-09898-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-023-09898-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-023-09898-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T16:21:22Z","timestamp":1716999682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-023-09898-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["9898"],"URL":"https:\/\/doi.org\/10.1007\/s10928-023-09898-0","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"type":"print","value":"1567-567X"},{"type":"electronic","value":"1573-8744"}],"subject":[],"published":{"date-parts":[[2024,2,3]]},"assertion":[{"value":"30 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F. Schaedeli Stark, M. Derks, C. Chavanne, and H.E. Silber Baumann are employees of F. Hoffmann-La Roche Ltd. K. Jolling, H.M. Lagraauw, L. Lindbom, and K. Prins are employees of qPharmetra LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}